MARPAI REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS

Company continues to drive towards profitability

TAMPA, Fla., Aug. 7, 2024 /PRNewswire/ — Marpai, Inc. (“Marpai” or the “Company”) (OTCQX: MRAI), a technology platform company, which operates as a national Third-Party Administrator (TPA) through its subsidiaries and is transforming the $22 billion TPA market by offering affordable, intelligent, healthcare solutions to self-funded employer health plans, announced financial results for the second quarter of 2024. The Company expects to hold a webcast to discuss the results on August 8, 2024.

Q2 2024 Financial Highlights:

  • Net revenues were approximately $7.2 million for the three months ended June 30, 2024, down $2.9 million, or 28% lower year over year, compared to the three months ended June 30, 2023.
  • Operating expenses were $14.3 million for the three months ended June 30, 2024 (including a charge for the impairment of goodwill and intangibles of $7.6 million), higher by $3.4 million, or 32% higher year over year compared to the three months ended June 30, 2023.
  • Operating loss was $12.3 million for the three months ended June 30, 2024, higher by $5.0 million, or 69% higher year over year compared to the three months ended June 30, 2023.
  • Net loss was $13.0 million for the three months ended June 30, 2024, higher by $5.5 million, or 72% higher year over year compared to the three months ended June 30, 2023.
  • Basic and diluted earnings per share were ($1.23) for the three months ended June 30, 2024, down ($0.13) per share year over year compared to the three months ended June 30, 2023.

“The Company continues to show progress towards our goal of profitability,” said Damien Lamendola, Chief Executive Officer of Marpai. “Additionally, our new sales team has been hitting the pavement and have set up a strong sales pipeline for Q1 2025 which we expect we will highlight after the third quarter.”

John Powers, Marpai President commented, “The Marpai operations team has executed on our performance actions. Our customer service metrics and claim processing key process indicators (KPIs) have seen tremendous improvement year over year. Moreover, our clients and potential clients have recognized the impact of our Marpai Saves initiatives which drive down the overall cost of healthcare benefits.”

Webcast and Conference Call Information

Marpai expects to host a conference call and webcast on Thursday, August 8, 2024, at 8:30 a.m. ET to review the Company’s operational and financial highlights for its second quarter ended June 30, 2024.

Investors interested in listening to the conference call may do so by dialing (800)-836-8184 for domestic callers or +1-646-357-8785 for international callers, or via webcast: https://app.webinar.net/lrwPxYJnvpY

About Marpai, Inc.

Marpai, Inc. (OTCQX: MRAI) is a technology platform company which operates subsidiaries that provide TPA and value-oriented health plan services to employers that directly pay for employee health benefits. Primarily competing in the $22 billion TPA sector serving self-funded employer health plans representing over $1 trillion in annual claims. Through its Marpai Saves initiative, the Company works to deliver the healthiest member population for the health plan budget. Operating nationwide, Marpai offers access to leading provider networks including Aetna and Cigna and all TPA services. For more information, visit www.marpaihealth.com, the content of which is not incorporated by reference into this press release. Investors are invited to visit https://www.ir.marpaihealth.com

Forward-Looking Statement Disclaimer

This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties. Forward-looking statements can be identified through the use of words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “guidance,” “may,” “can,” “could”, “will”, “potential”, “should,” “goal” and variations of these words or similar expressions. For example, the Company is using forward looking statements when it discusses the Q1 2025 sales pipeline and the expected timing of its highlighting of its pipeline. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect Marpai’s current expectations and speak only as of the date of this release. Actual results may differ materially from Marpai’s current expectations depending upon a number of factors. These factors include, among others, adverse changes in general economic and market conditions, competitive factors including but not limited to pricing pressures and new product introductions, uncertainty of customer acceptance of new product offerings and market changes, risks associated with managing the growth of the business. Except as required by law, Marpai does not undertake any responsibility to revise or update any forward-looking statements whether as a result of new information, future events or otherwise.

More detailed information about Marpai and the risk factors that may affect the realization of forward-looking statements is set forth in Marpai’s filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov.

 

MARPAI, INC. AND SUBSIDIARES 

CONDENSED CONSOLIDATED BALANCE SHEET

(in thousands, except share and per share data)

(Unaudited)

June 30, 2024

December 31, 2023

ASSETS:

Current assets:

Cash and cash equivalents

$                      1,293

$                            1,147

Restricted cash

12,762

12,345

Accounts receivable, net of allowance for credit losses of $0 and $25

805

1,124

Unbilled receivable

568

768

   Due from buyer for sale of business unit

800

800

Prepaid expenses and other current assets

967

901

Total current assets

17,195

17,085

Property and equipment, net

546

611

Capitalized software, net

933

2,127

Operating lease right-of-use assets

2,253

2,373

Goodwill

3,018

Intangible assets, net

5,177

Security deposits 

1,267

1,267

Other long-term asset

22

22

Total assets

$                    22,216

$                          31,680

LIABILITIES AND STOCKHOLDERS’  (DEFICIT) EQUITY

Current liabilities:

Accounts payable

$                      3,172

$                            4,649

Accrued expenses

2,643

2,816

Accrued fiduciary obligations

9,948

11,573

Deferred revenue

1,295

661

Current portion of operating lease liabilities

541

512

Current portion of convertible debenture, net

1,089

Other short-term liabilities

632

Total current liabilities

18,688

20,843

Other long-term liabilities

20,144

19,401

Convertible debenture, net of current portion

4,451

Operating lease liabilities, net of current portion

3,405

3,684

Deferred tax liabilities

1,190

1,190

Total liabilities

47,878

45,118

COMMITMENTS AND CONTINGENCIES

STOCKHOLDERS’ (DEFICIT) EQUITY

Common stock, $0.0001 par value, 227,791,050 shares authorized; 11,037,038
   and 7,960,938 issued and outstanding at June 30, 2024 and
   December 31, 2023, respectively (1)

1

1

Additional paid-in capital

68,455

63,307

Accumulated deficit

(94,118)

(76,746)

Total stockholders’ (deficit) equity

(25,662)

(13,438)

Total liabilities and stockholders’ (deficit) equity

$                    22,216

$                          31,680

 

MARPAI, INC. AND SUBSIDIARES 

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except share and per share data)

(Unaudited)

Three Months Ended 

June 30, 2024

June 30, 2023

Revenue

$                      7,189

$                          10,047

Costs and expenses

Cost of revenue (exclusive of depreciation and amortization
   shown separately below)

5,174

6,430

General and administrative

3,721

5,725

Sales and marketing

436

1,473

Information technology

1,210

1,319

Research and development

8

523

Depreciation and amortization

914

1,003

Impairment of goodwill and intangible assets 

7,588

Loss on disposal of assets

344

Facilities

411

500

Total costs and expenses

19,462

17,317

Operating loss

(12,273)

(7,270)

Other income (expenses)

Other income

120

50

Interest expense, net

(872)

(333)

Foreign exchange (loss) gain

(1)

(3)

Loss before provision for income taxes

(13,026)

(7,556)

Income tax expense

Net loss

$                  (13,026)

$                           (7,556)

Net loss per share, basic & fully diluted

$                      (1.23)

$                             (1.10)

Weighted average common shares outstanding, basic and
   diluted

10,626,516

6,844,778

MARPAI, INC. AND SUBSIDIARES 

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except share and per share data)

(Unaudited)

Six Months Ended 

June 30, 2024

June 30, 2023

Revenue

$                    14,574

$                          19,719

Costs and expenses

Cost of revenue (exclusive of depreciation and amortization
   shown separately below)

10,045

12,838

General and administrative

7,142

10,951

Sales and marketing

1,038

3,652

Information technology

2,334

3,506

Research and development

15

1,024

Depreciation and amortization

1,865

2,047

Impairment of goodwill and intangible assets 

7,588

Loss on disposal of assets

344

Facilities

885

1,150

Total costs and expenses

30,912

35,512

Operating loss

(16,338)

(15,793)

Other income (expenses)

Other income

240

101

Interest expense, net

(1,270)

(718)

Foreign exchange (loss) gain

(4)

(19)

Loss before provision for income taxes

(17,372)

(16,429)

Income tax expense

Net loss

$                  (17,372)

$                         (16,429)

Net loss per share, basic & fully diluted

$                      (1.73)

$                             (2.70)

Weighted average common shares outstanding, basic and
   diluted

10,016,146

6,080,200

 

MARPAI, INC. AND SUBSIDIARES 

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands, except share and per share data)

(Unaudited)

Three Months Ended

June 30, 2024

June 30, 2023

Cash flows from operating activities:

Net loss

$                  (17,372)

$                         (16,429)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation and amortization

1,865

2,046

Loss on disposal of assets

344

Loss on sale of receivables

306

Share-based compensation

2,421

990

Shares issued to vendors in exchange for services

79

Amortization of right-of-use asset

120

1,049

Gain on termination of lease

33

Impairment of goodwill and intangible assets

7,588

Non-cash interest

646

776

Amortization of debt discount

62

Changes in operating assets and liabilities:

Accounts receivable and unbilled receivable

519

74

Prepaid expense and other assets

(66)

425

Security deposit

(14)

Accounts payable

(1,477)

729

Accrued expenses

(173)

(235)

Accrued fiduciary obligations

(1,625)

1,713

Operating lease liabilities

(250)

(1,343)

Due To related party

(4)

Other liabilities

731

1,028

Net cash used in operating activities

(6,705)

(8,739)

Cash flows from investing activities:

Disposal of property and equipment

18

Net cash provided by (used in) investing activities

18

Cash flows from financing activities:

Proceeds from issuance of common stock in a public offering, net

6,432

Proceeds from stock options exercises

1,509

Proceeds from issuance of convertible debentures 

5,978

Payments of convertible debenture issuance costs

(499)

Payments to buyer of receivables

(1,816)

Proceeds from issuance of common stock in a public offering, net

(631)

Proceeds from issuance of common stock in a private offering, net

2,727

Net cash provided by financing activities

7,268

6,432

Net decrease in cash, cash equivalents and restricted cash

563

(2,289)

Cash, cash equivalents and restricted cash at beginning of period

13,492

23,117

Cash, cash equivalents and restricted cash at end of period

$                    14,055

$                          20,828

Reconciliation of cash, cash equivalents, and restricted cash reported in
   the condensed consolidated balance sheet

Cash and cash equivalents

$                      1,293

$                            8,726

Restricted cash

12,762

12,102

Total cash, cash equivalents and restricted cash shown in the condensed
   consolidated statement of cash flows

$                    14,055

$                          20,828

Supplemental disclosure of cash flow information

Cash paid for interest

$                      1,259

$                                 —

Supplemental disclosure of non-cash activity

Measurement period adjustment to Goodwill

$                           —

$                               198

 

(PRNewsfoto/Marpai)

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/marpai-reports-second-quarter-2024-financial-results-302217200.html

SOURCE Marpai